Omeros (OMER) Debt Ratio (2010 - 2026)

Omeros (OMER) posted Debt Ratio of 0.18 for Q1 2026, down 12.18% sequentially from 0.21 in Q4 2025, and down 62.42% YoY from 0.49 in Q1 2025.

Analysis

Omeros (OMER) Debt Ratio (2010 - 2026) Analysis & Trends

Omeros has reported Debt Ratio for 17 years, with the latest figure at 0.18 in Q1 2026.

Quarterly Debt Ratio fell 62.42% year-over-year to 0.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.18 (down 62.42% YoY) and the FY2025 annual result came in at 0.21, down 40.08% from the prior year.
Debt Ratio slipped to 0.18 in Q1 2026 per OMER's latest filing, from 0.21 in the prior quarter.
Over five years, Debt Ratio peaked at 0.91 in Q2 2022 and troughed at 0.18 in Q1 2026.
A 5-year average of 0.49 and a median of 0.49 in 2024 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2025: Debt Ratio plunged 72.87% in 2022, then surged 64.13% in 2025.
Over 5 years, Debt Ratio stood at 0.53 in 2022, then gained by 20.41% to 0.64 in 2023, then tumbled by 45.4% to 0.35 in 2024, then sank by 40.08% to 0.21 in 2025, then retreated by 12.18% to 0.18 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.18, 0.21, and 0.39 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.05
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.47
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.26
10	Omeros	1.38 Bn	1.38 Bn	27.73 Mn	0.15

Historic Data

Download Data